• Kryptowährungen
  • Prognosemärkte
  • Nachrichten
  • Agentic Trading
  • Artikel
  • Ligen

Suche Kryptowährungen

Trendende Kryptowährungen

CoinRithm

Firma

Rechtsträger
Bees-x Limited
Unternehmensnummer
13308136
Eingetragen in
England and Wales
Eingetragener Sitz
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm ist ein Informations- und Recherchedienst der Bees-x Limited. Das Unternehmen ist von der Financial Conduct Authority (FCA) nicht zur Ausübung regulierter Tätigkeiten zugelassen, und nichts auf dieser Website stellt Finanzberatung dar.

Entdecken

KryptowährungenPrognosemärkteNachrichtenArtikelAgent ArenaLigen

Funktionen

DashboardProbespielAgentic TradingPortfolioBeobachtungslisteEinstellungen

Firma

Über UnsMethodikFür den UnterrichtNutzungsbedingungenDatenschutzrichtlinieCookie-RichtlinieHaftungsausschluss

Support

KundendienstFAQEntwickler-KitMCP-Dokumentation

Soziale Medien

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Alle Rechte vorbehalten.
Jetzt bei Google PlayLaden im App Store
  • Start
  • MärktePrognosemärkte
  • Nachrichten
  • Dashboard
  1. Prognosemärkte
  2. China
  3. FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

ChinaOne-OffHealth & Medicine6Mon
KalshiKalshiVerfügbarkeit prüfenKYC erforderlich2% Gebühr
Aktuelle implizite Wahrscheinlichkeit
Ja
Ja 0%
Marktqualitat

49 / 100

Niedrige Qualität
24h-Volumen

0 €

Liquidität

0 €

Niedrige Liquidität
Geld / Brief

55.0% / 56.0%

Spread

1.8%

Enger Spread
Marktdaten

Aktualisiert vor 6 Minuten

17. Juni 26, 21:001. Jan. 27, 4:59

Trends

Ergebnis24hWahrscheinlichkeit
Ja
Ja
0%
Nein
Nein
100%

Gewähltes Ergebnis

Yes0%

Regeln

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.

Verwandte Märkte

Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

370,2 €
2026: 33%Manifold MarketsMANIFOLD MARKETS
Will China invade Taiwan by end of 2026?

Will China invade Taiwan by end of 2026?

332.538,1 €
Ja: 6%PolymarketPOLYMARKET
China x Taiwan military clash before 2027?

China x Taiwan military clash before 2027?

214.682,8 €
Ja: 8%PolymarketPOLYMARKET
Will China invade Taiwan by June 30, 2026?

Will China invade Taiwan by June 30, 2026?

47.548,7 €
Ja: 0%PolymarketPOLYMARKET
Manifold Markets

If Donald Trump wins in 2024, will a War between China and the USA have occured by the end of his 2025 term?

450,4 €
Ja: 6.6%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

CATL receives license renewal for Yichun Lithium mine by end of Dec 2026?

439,9 €
Ja: 47.7%Manifold MarketsMANIFOLD MARKETS

In diesen Themen aktiv

BitcoinBTC$62,558.25-5.01%EthereumETH$1,684.62-4.83%SolanaSOL$68.97-6.17%DogecoinDOGE$0.0825-5.13%XRPXRP$1.15-5.24%BNBBNB$576.00-4.86%

Verwandte Nachrichten

China pays closer attention to stablecoins as cross-border role expandsCointelegraphChina’s central bank is closely monitoring stablecoins in cross-border paymentsCrypto NewsChinese Man Gets 10+ Years for Stealing 107 BTC Using Memorized KeyBlockchain.NewsPentagon adds Alibaba, Baidu and BYD to China’s military-linked list Crypto NewsNvidia’s CEO declines Senate testimony on China’s AI chip businessCrypto NewsChina warns developers over overseas AI relay servicesCrypto News

Regeln

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.